Warning letter
The Compounding Pharmacy of America: warning letter of Jun 9, 2016
FDA warning letter 476703 · New Orleans District Office
Key facts
| Reference number | 476703 |
|---|---|
| Company | The Compounding Pharmacy of America |
| Subject | CGMP/Compounded Drugs/Misbranding |
| Issue date | Jun 9, 2016 |
| Posted date | Jun 14, 2016 |
| Issuing office | New Orleans District Office |
| Product type | Drugs |
| CFR sections cited | 211.166(a), 201.115, 210, 211, 211.28(a), 211.42(c)(10)(ii), 211.42(c)(10)(iii), 211.42(c)(10)(iv), 211.42(c)(10)(v), 211.113(b) |
| Inspection city | Knoxville |
| Inspection ZIP | 37919 |
| Inspection start date | May 12, 2015 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: